Ataraxis AI has raised $20.4 million in Series A funding, led by AIX Ventures with backing from Thiel Bio, Founders Fund, and other industry leaders. The investment will accelerate the launch of Ataraxis Breast, the first AI-native prognostic and predictive platform for breast cancer, which has been clinically validated to be 30% more accurate than current medical standards.